Tumorigenesis and attendant safety risks are significant concerns of induced pluripotent stem cell (iPSC)-based therapies. Thus, it is crucial to evaluate iPSC proliferation, differentiation, and tumor formation after transplantation. Several approaches have been employed for tracking the donor cells, including fluorescent protein and luciferase, but both have limitations. Here, we introduce a protocol using iRFP genetic labeling technology to track tumor formation of iPSCs in skeletal muscle after CRISPR/Cas9 gene editing.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-0716-0364-2_7DOI Listing

Publication Analysis

Top Keywords

irfp genetic
8
genetic labeling
8
labeling technology
8
technology track
8
skeletal muscle
8
tumor formation
8
track tumorogenesis
4
tumorogenesis transplanted
4
transplanted crispr/cas9-edited
4
crispr/cas9-edited ipsc
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!